Full Press Release Details
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, August 8th @ 4:30 PM ET
| Domestic: | 1-800-267-6316 |
| International: | 1-203-518-9783 |
| Conference ID: | CRNXQ2 |
Participants can use the dial-in numbers above OR access the call via live webcast on the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants dial-in or register at least 15 minutes prior to scheduled start of the call.
The webcast will be archived on the Investor Relations sections of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.
Head of Investor Relations
Head of Corporate Communications
Source: Crinetics Pharmaceuticals, Inc.